Health Equity & Access Weekly Roundup: July 24, 2026

5 FDA Firsts From June

The FDA cleared 5 first-in-class or first-in-kind therapies in June 2026, spanning infectious disease, oncology, and rare disease. The month opened with the June 1 approval of ensitrelvir (Xocova; Shionogi), the first oral option for COVID-19 postexposure prophylaxis in patients 12 and older; in the phase 3 SCORPIO-SR trial of 2387 exposed but uninfected household contacts, the once-daily regimen cut the risk of symptomatic COVID-19 by 67% through day 10 compared with placebo.

On June 18, the agency approved tebipenem pivoxil (Utebzi; GSK/Spero Therapeutics), the first oral carbapenem antibiotic for complicated urinary tract infections, after the PIVOT-PO trial showed noninferiority to intravenous imipenem-cilastatin (58.5% vs 60.2% success). Five days later, the FDA cleared the first generic rifapentine (Priftin; Sanofi-Aventis US) for active and latent tuberculosis.

The following week brought 2 more firsts: on June 24, palbociclib (Ibrance; Pfizer) became the first CDK4/6 inhibitor approved as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer regardless of HER2 status, cutting the risk of progression or death by 24% in the PATINA trial, and on June 26, veligrotug-vvze (Lumvoa; Viridian) became the first thyroid eye disease treatment labeled for both active and chronic disease, with proptosis responder rates as high as 70% vs 5% to 9% for placebo. Collectively, the approvals expand oral and outpatient treatment pathways across disease areas that have faced longstanding gaps in care access.

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

The FDA's Pharmacy Compounding Advisory Committee met July 23-24 to consider whether 7 unapproved peptides—BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, and semax—should be added to the agency's 503A Bulks List, a designation that would allow state-licensed compounding pharmacies to prepare the substances for individual patients under valid prescriptions.

None of the compounds has generated the clinical evidence typically required for FDA approval. However, several, particularly BPC-157 and TB-500, have become popular in wellness, longevity, and biohacking circles despite limited supporting data. Ahead of the meeting, FDA's Center for Drug Evaluation and Research completed its own review and recommended against adding any of the 7 peptides, citing a near-total absence of human clinical data and unresolved safety concerns, including immunogenicity and, for at least 1 compound, potential tumor-promoting activity; the recommendation is nonbinding.

Even a favorable vote would not create immediate access, as a full notice-and-comment rulemaking process would likely not conclude before 2027 or 2028. The review unfolds amid broader policy debate, as HHS Secretary Robert F. Kennedy Jr has voiced support for expanding peptide access, and the FDA reconstituted the committee in June with several new members reported to have ties to peptide-related businesses.

Dermatology Practices Absorb Rising Prior Authorization Costs

Dermatology practices spend a mean of 13 hours a week and file about 39 prior authorization requests per physician annually just to initiate medications already prescribed, and roughly 1 in 3 of those requests is still denied, according to Jane M. Grant-Kels, MD, FAAD, professor and vice chair of dermatology at UConn Health.

About 40% of practices now employ staff dedicated solely to prior authorization filings, yet when insurers use artificial intelligence to review requests, Grant-Kels said denial rates have risen as much as 16-fold; for patients with extensive psoriasis, treatment delays tied to step therapy can prolong work disability, and inaccurate Medicaid provider directories further limit access in states where only a third to half of dermatologists participate. State-level reforms enacted in 2025 in Indiana, Iowa, Nebraska, Alaska, Montana, and Colorado have streamlined prior authorization processes, in some cases requiring physician rather than nonclinical adjudication, though Grant-Kels said further federal and state action is needed.

Health plans point to their own progress: participating insurers eliminated 11% of prior authorizations, or about 6.5 million requests, across covered markets since a June 2025 reform commitment with HHS and CMS, with reductions exceeding 15% in Medicare Advantage, and a standardized electronic prior authorization framework is targeted for broader adoption by January 2027. Grant-Kels also linked the burden to reimbursement policy, arguing that work relative value units undervalue the cognitive workload behind dermatologic diagnosis relative to procedural care, compounding pressure on practices in lower-reimbursement specialties and geographies.

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

President Donald Trump announced a phased tariff schedule for imported generic drugs, ending the category's prior exemption from his administration's pharmaceutical trade agenda. In a Truth Social post, Trump said generics would remain tariff-free for a 2-year transition period beginning August 1, 2026, before facing a 100% tariff for 1 year and a 200% tariff thereafter, a timeline intended to pressure manufacturers into establishing US production; tariffs on patented, branded drugs, which can reach 100%, remain unchanged. Generic drugs account for about 90% of US prescriptions but a small share of overall drug spending, and because manufacturers typically operate on thin margins, analysts have warned that broad tariffs could disproportionately affect affordability and availability compared with tariffs focused on higher-margin branded medicines.

The announcement follows earlier reporting in which health policy analysts cautioned that tariffs could raise costs for both branded and generic drugs, given that roughly 80% of active pharmaceutical ingredients used in the US are sourced from China and India. Because Medicaid inflation rebates and the 340B program limit manufacturers' ability to raise prices on many generics, analysts have warned that added tariff costs could instead push some manufacturers to exit low-margin markets, risking shortages of drugs such as generic sterile injectables, including older cancer therapies. Building and validating new US manufacturing capacity typically takes longer than the 2-year runway proposed, leaving 2028 as a pivotal year for drug affordability and supply chain stability.

Digital QI Intervention Modestly Improves Low-Density Lipoprotein Cholesterol (LDL-C) Control in Patients With ASCVD

A pragmatic, cluster-randomized trial published in JAMA Cardiology found that a digitally enabled, multifaceted quality improvement intervention modestly improved LDL-C control and increased use of intensive lipid-lowering therapy among patients with established atherosclerotic cardiovascular disease (ASCVD), though many patients remained above guideline targets. Investigators randomized 28 public and private outpatient clinics in Brazil to the intervention, which combined previsit screening, electronic clinical decision support, audit-and-feedback mechanisms, and clinician and patient engagement tools, or to routine care; 1465 adult patients with established ASCVD were enrolled and followed for 6 months.

At 6 months, mean LDL-C was 76.3 mg/dL in the intervention group vs 85.6 mg/dL in the control group, an adjusted difference of −6.62 mg/dL (95% CI, −11.11 to −2.13; P = .004), and intervention patients were more likely to reach LDL-C below 50 mg/dL (23.5% vs 13.4%) and to achieve a 50% or greater LDL-C reduction (18.6% vs 13.4%); prescribing of intensive and combination lipid-lowering therapy was also significantly higher, though no significant between-group difference in major cardiovascular events emerged over follow-up. The researchers noted limitations, including a predominantly specialty-clinic setting, a 6-month follow-up too short to assess long-term outcomes, and the absence of a prespecified cost-effectiveness analysis.